lutetium has been researched along with Response Evaluation Criteria in Solid Tumors in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, WR; Benz, MR; Calais, J; Eiber, M; Fendler, WP; Gafita, A; Herrmann, K; Hui, W; Murthy, V; Rauscher, I; Weber, M; Weber, WA | 1 |
| Berntzen, DT; Løitegård, T; Thiis-Evensen, E | 1 |
| Blažević, A; Brabander, T; de Herder, WW; Feelders, RA; Hofland, J; Kam, BLR; Teunissen, JJM; Zandee, WT | 1 |
3 other study(ies) available for lutetium and Response Evaluation Criteria in Solid Tumors
| Article | Year |
|---|---|
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2022 |
The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Coordination Complexes; Female; Gastrins; Glucagon; Humans; Insulin; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreas; Pancreatic Neoplasms; Quality of Life; Radiation Dosage; Radioisotopes; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Vasoactive Intestinal Peptide | 2019 |